Lipidomic analysis of plasma samples from women with polycystic ovary syndrome

Metabolomics

Volumn 11, Issue 3, 2015, Pages 657-666

  Haoula, Zeina ^b   Ravipati, Srinivasarao ^a   Stekel, Dov J ^a   Ortori, Catharine A ^a   Hodgman, Charlie ^a   Daykin, Clare ^a,c   Raine Fenning, Nick ^b   Barrett, David A ^a   Atiomo, William ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MetaboConsult UK   (United Kingdom)

Author keywords

Biomarkers; Lipidomics; Menstrual cycle; Polycystic ovary syndrome

Indexed keywords

EID: 84939887404     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-014-0726-y     Document Type: Article

References (38)

1. Atiomo, W., & Daykin, C. A. (2012). Metabolomic biomarkers in women with polycystic ovary syndrome. A pilot study. Molecular Human Reproduction,18, 546–553.
2. Atiomo, W., Khalid, S., Parameshwaran., Houda, M., & Layfield, R. (2009a). Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: A systematic review. BJOG: An International Journal of Obstetrics and Gynaecology,116, 137–143.
3. Atiomo, W. U., Khalid, S., Ziauddin, A., Tooth, D., & Layfield, R. (2009b). Framework for a systems approach to proteomic biomarker profiling in polycystic ovary syndrome. Expert Review of Proteomics,6, 469–499.
4. Banaszewska, B., Antoni, J., Pawelczyk, L., Robert, Z., & Spaczynski, Z. (2006). Lipids in polycystic ovary syndrome role of hyperinsulinemia and effects of metformin. Journal of Obstetrics and Gynaecology,194, 1266–1272.
5. Bloom, M. S., Schisterman, E. F., & Hediger, M. L. (2007). The use and misuse of matching in case-control studies: The example of polycystic ovary syndrome. Fertility and Sterility,88(3), 707–710.
6. Bogdonov, M., Wayne, L.,Wang, T., Matson, R., Saunders, S.S., Bressman & Flintbeal, M. (2008). Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain, 131, 389–396.
7. Chen, Z. J., Zhao, H., He, L., Shi, Y., et al. (2011). Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nature Genetics,43, 55–59.
8. Choi, B. C., Kim, Y. S., Kim, M. S., Chung, M. K., Choi, C. H., & Baek, K. H. (2007). Identification of over expressed proteins by proteomic analysis using human follicular fluids derived from polycystic ovary syndrome (PCOS) patients. Fertility and Sterility,88, S180.
9. Corton, M., Botella-Carretero, J. I., Lopez, J. A., Camafeita, E., San Milla’n, J. L., Escobar-Morreale, H. F., & Peral, B. (2008). Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Human Reproduction, 23, 651–61.
10. Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Reviews,18, 774–800.
11. Eng, J. (2007). ROC analysis: Web-based calculator for ROC curves. http://www.jrocfit.org. Accessed Mar 2014.
12. Friedman, J., Hastie, T., & Tibshirani, R. (2010). Regularization Paths for Generalized Linear Models via Coordinate Descent. Journal of Statistical Software,33, 1–22.
13. Goodarzi, M, O. (2008). Looking for polycystic ovary syndrome genes: rational and best strategy. Seminars in Reproductive Medicine, 26, 5-13.
14. Han, X., Abendschein, D. R., Kelley, J. G., & Gross, R. W. (2000). Diabetes-induced changes in specific lipid molecular species in rat myocardium. Biochemical Journal,352, 79–89.
15. Hughes, C., Elgasim, M., Layfield, R., & Atiomo, W. (2006). Genomic and post-genomic approaches to polycystic ovary syndrome-progress so far: Mini review. Human Reproduction,21, 2766–2775.
16. Insenser, M., Martínez-García, M. A., Montes, R., San-Millan, J. R., & Escobar-Morreale, H. F. (2010). Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. Journal of Clinical Endocrinology and Metabolism,95, 3863–3870.
17. Kim, J. Y., Park, J. Y., Kim, O. Y., Ham, B. M., Kim, H. J., Kwon, D. Y., et al. (2010). Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). Journal of Proteome Research,9, 4368–4375.
18. Kolesnick, R. (1994). Signal transduction through the sphingomyelin pathway. Molecular and Chemical Neuropathology,21(2–3), 287–297.
19. Legro, R. S., Driscoll, D., Strauss, J. F, 3rd, et al. (1998). Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proceedings of the National Academy of Sciences USA,95, 14956–14960.
20. Luque-Ramirez, M., San Millan, J. L., & Escobar-Morreale, H. F. (2006). Genomic variants in polycystic ovary syndrome. Clinica Chimica Acta,366, 14–26.
21. Ma, X., Fan, L., Meng, Y., Hou, Z., Mao, Y. D., Wang, W., et al. (2007). Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Molecular Human Reproduction,13, 527–535.
22. March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I., Norman, R. J., & Davies, M. J. (2010). The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction,25, 544–551.
23. Matharoo-Ball, B., Hughes, C., Lancashire, L., Tooth, D., Ball, G., Creaser, C., et al. (2007). Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. Journal of Proteome Research,6, 3321–3328.
24. Meikle, P. J., & Christopher, M. J. (2011). Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Current Opinion in Lipidology,22, 210–215.
25. Mumford, S. L., Schisterman, E. F., Siega-Riz, A.M., Browne, R.W., Gaskins, A. J., Trevisan, M., Steiner, A, Z., Daniels, J. L., Zhang, C., Perkins, N. J., & Wactawski-Wende, J. (2010). A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones during the menstrual cycle: Findings from the BioCycle study. Journal of Clinical Endocrinology and Metabolism,95, E80–E5.
26. Munder, P. G., Modolell, M., Andreesen, R., Weltzien, H. U., & Westphal, O. (1979). Lysophosphatidylcholine (Lysolecithin) and its synthetic analogues. immunemodulating and other biologic effects. Springer Seminars in Immunopathology,203, 187–203.
27. Pasquali, R., Stener-Victorin, E., Yildiz, B. O., Duleba, A. J., Hoeger, K., Mason, H., et al. (2011). PCOS Forum: research in polycystic ovary syndrome today and Tomorrow. Clinical Endocrinology,74, 424–433.
28. Postle, A. D. (2012). Lipid metabolism and therapy. Current Opinion in Clinical Nutrition & Metabolic Care,15, 127–133.
29. Punnonen, R. (1978). Total serum cholesterol, triglycerides and phospholipids during the normal menstrual cycle. International Journal of Gynaecology and Obstetrics,15, 296–298.
30. Quehenberger, O., & Dennis, E. (2011). The human plasma lipidome. The New England Journal of Medicine,365, 1812–1823.
31. Reddy, J. K., & Rao, M. S. (2006). Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology,290, 852–858.
32. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility,81, 19–25.
33. Sun, L., Hu, W., Liu, Q., Hao, Q., Sun, B., Zhang, Q., et al. (2012). Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. Journal of Proteome Research,11, 2937–2946.
34. Urbanek, M., Legro, R. S., & Driscoll, D. A. (1999). Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. Proceedings of the National Academy of Sciences USA,96, 8573–8578.
35. Wenk, M. R. (2005). The emerging field of lipidomics. Nature Review Drug Discovery,4, 594–610.
36. Wild, R. A., Rizzo, M. D., Clifton, S., & Carmina, C. (2011). Lipid levels in polycystic ovary syndrome: Systematic review and meta-analysis. Fertility and Sterility,95, 1073–1079.
37. Woods, N. G., & Graham, T. E. (1986). Effect of menstrual cycle phase and exercise training on serum lipids. Canadian Journal of Applied Sport Sciences,11, 88–93.
38. Zhao, Y., Fu, L., Li, R., Wang, L. N., Yang, Y., Liu, N. N., et al. (2012). Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: Plasma metabolomics analysis. BMC Medicine,30(10), 153.